Finance ❯ Stock Market ❯ Market Reactions

Investor Losses

Stock Price Decline Legal Claims Trading Volume Short Selling Financial Statements Stock Price Movements

Skye Bioscience Faces Investor Class Actions as Firms Court Shareholders Before Jan. 16 Deadline

Plaintiffs base their claims on Skye’s October 6 nimacimab data release that preceded a 60% one-day share decline.